Notable Labs to Present Analysis of Hematologic Oncology Drug Sensitivity Data
"This webinar will highlight the integration of three technologies: a flow-cytometry drug sensitivity screen, DNA-Seq, and RNA-Seq," said CEO Laurie Heilmann.
- "This webinar will highlight the integration of three technologies: a flow-cytometry drug sensitivity screen, DNA-Seq, and RNA-Seq," said CEO Laurie Heilmann.
- "By augmenting a stand-alone drug sensitivity screen with multi-omic data, Notable Labs is amassing a continually-growing dataset that ultimately will provide utility for drug development and patient care in AML and other hematologic oncology indications."
- The webinar will cover how this dataset, containing samples with matched drug sensitivity, gene expression, and variant data, enables researchers to look at the relationships between different data types.
- Notable's functional precision medicine platform will advance drug development and enable pharmaceutical companies to get new therapies topatientsfaster.